Accelrys has acquired Ireland-based QUMAS for approximately $50 million to enhance its compliance software offerings within the life sciences sector.
Target Overview
On December 9, 2013, Accelrys (NASDAQ: ACCL) announced its acquisition of QUMAS, a company based in Ireland. Accelrys is a prominent provider of scientific innovation lifecycle management software designed for organizations focusing on scientific innovation to maintain their competitive edge. QUMAS is recognized globally for its cloud-based and on-premises compliance software that supports regulatory and quality operations, specifically within life sciences and other highly regulated sectors.
The acquisition involved Accelrys paying approximately $50 million in cash for all outstanding capital stock of QUMAS. This strategic move is set to enhance Accelrys’ capabilities in delivering comprehensive document and process management solutions crucial for compliance and quality management within science-driven industries.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Ireland
The life sciences sector in Ireland has been experiencing significant growth, bolstered by a strong regulatory framework and government support initiatives. Ireland has emerged as a hub for multinational pharmaceutic
Similar Deals
Medica Group PLC → Global Diagnostics Ireland and Global Vision
Novartis AG → Avidity Biosciences, Inc.
2026
Accelrys
invested in
QUMAS
in 2013
in a Merger deal
Disclosed details
Transaction Size: $50M